Spyre Therapeutics, Inc. (SYRE)
NASDAQ: SYRE · Real-Time Price · USD
70.17
+0.75 (1.08%)
May 4, 2026, 1:02 PM EDT - Market open
Spyre Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
102
Market Cap
6.05B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 886.00K | -1.44M | -61.96% |
| Dec 31, 2022 | 2.33M | -16.41M | -87.57% |
| Dec 31, 2021 | 18.74M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Mirum Pharmaceuticals | 521.31M |
| Rhythm Pharmaceuticals | 189.76M |
| Protagonist Therapeutics | 46.02M |
| Centessa Pharmaceuticals | 15.00M |
| CG Oncology | 4.04M |
SYRE News
- 2 days ago - Spyre Therapeutics Announces Grants of Inducement Awards - GlobeNewsWire
- 17 days ago - Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $463.5 Million - GlobeNewsWire
- 19 days ago - Spyre Therapeutics Announces Pricing of Upsized $403.0 Million Public Offering of Common Stock - GlobeNewsWire
- 20 days ago - Spyre Therapeutics Announces Proposed Public Offering of its Common Stock - GlobeNewsWire
- 20 days ago - Spyre Therapeutics Breaks Higher On Positive Data From Ulcerative Colitis Drug - Benzinga
- 21 days ago - Spyre Therapeutics Transcript: Study result - Transcripts
- 21 days ago - Spyre Announces Potential Best-in-Class SPY001 Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients - GlobeNewsWire
- 23 days ago - Spyre Therapeutics to Host Conference Call to Report SPY001 Part A Induction Topline Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients on April 13, 2026 - GlobeNewsWire